ArticleAnnals of medicine and surgery (2012)2025
FDA approval of EBGLYSS™ (lebrikizumab-lbkz) to treat moderate-to-severe atopic dermatitis in adults and children aged 12 and older.
Article in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Food and Drug Administration has approved EBGLYSS™ (lebrikizumab-lbkz) for the treatment of patients of moderate-to-severe atopic dermatitis (AD) (eczema) who weigh at least 88 pounds (40 kg). AD is a chronic, inflammatory, pruritic skin disorder affecting up to 20% of children and 3% of adults worldwide. Lebrikizumab, an interleukin-13 inhibitor, has shown promising results in improving symptoms, quality of life, and disease severity in patients with moderate-to-severe AD. Administered via subcutaneous injection, lebrikizumab offers rapid symptom relief with potentially lower systemic side effects compared to other therapies. However, the drug development process carries inherent risks and uncertainties. Overall, lebrikizumab represents a valuable option for patients with AD, potentially enhancing their quality of life and confidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.